The "Global Next-Generation Biomanufacturing Market: Focus on Workflow, Product Type, Medical Applications, End Users, 5 Regional Data, 19 Countries' Data, and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.
The Global Next-Generation Biomanufacturing Market Report projects the market to grow at a significant CAGR of 10% during the forecast period, 2019-2029.
The rapid maturation of the biopharmaceutical sector denotes the increasing importance of biomanufacturing as the most basic procedure for the development and manufacture of biologic-based products. With increasing commercialization of biopharmaceuticals and the addition of more products in the development pipeline, biopharmaceutical companies are looking forward to adopting novel biomanufacturing strategies with an increased focus on balancing innovation in process design, performance, and efficiency with speed and cost.
The need for advanced biomanufacturing practices in order to meet the demand of the growing patient population has paved the way for the development of next-generation biomanufacturing products. Next-generation biomanufacturing products are designed to provide seamless services that are superior in terms of both quality and efficiency as compared to first-generation products. Increased funding from private investors and the government for the development of next-generation biomanufacturing facilities promoting rapid technological advancement in biomanufacturing products is one of the most prominent factors driving the growth of the next-generation biomanufacturing market.
One of the major trends of the next-generation biomanufacturing market is the shifting focus toward the adoption of single-use products, such as single-use bioreactors and single-use biocontainers. This is mainly attributed to the huge number of benefits associated with single-use products, with regard to cost savings, reduced risk of product contamination, and increased flexibility in multi-product facilities.
With more companies entering the next-generation biomanufacturing market through product innovations, several novel next-generation biomanufacturing products are expected to come up, actively driving the growth of the market in the upcoming years.
Expert Quote
The leading contributors in the global next-generation biomanufacturing market predominantly prefer partnerships and alliances to sustain the market competition and strengthen their business position. Most of the market leaders are collaborating with technology-based startups to gain their expertise in technology.
Research Highlights
The leading contributors to the global next-generation biomanufacturing market predominantly prefer partnerships and alliances to sustain the market competition and strengthen their business position. Most of the market leaders are collaborating with technology-based startups to gain their expertise in technology.
Monoclonal antibody product segment with relatively high market approval rates is dominating the next-generation biomanufacturing market, by the medical application. Monoclonal antibodies segment was valued at $6.66 billion in 2018, contributing to 45% of the total market share in 2018.
In terms of end-users, commercial-stage end-user dominated the global next-generation biomanufacturing market and was valued at $11.39 billion in 2018. On the other hand, for both commercial-stage end-users and preclinical and development stage end users, biopharmaceutical companies were the major contributor of revenue, followed by CMOs/CDMOs.
Among the different regions, North America leads the global next-generation biomanufacturing market in 2018, with the U.S. being the major contributor to revenue. In 2018, North America contributed 35.40% of the total market share and the U.S. alone contributed to more than 95.4% of its market share.
This market intelligence report provides a multidimensional view of the global next-generation biomanufacturing market in terms of market size and growth potential. This research report aims at answering various aspects of the global next-generation biomanufacturing market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of market expansion.
Story continues
Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities such as product launches, partnerships, and product approvals, among others. The research report provides a comprehensive analysis of the product sales, and manufacturers and trend analysis by segment and by region.
This report is a meticulous compilation of research on more than 10 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of the leading companies, market participants and vendors. The report also profiles 15 companies including several key players, such as Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, Eppendorf AG, Sartorius AG, GEA Group Aktiengesellschaft, bbi-biotech GmbH, Esco Group of Companies, Pierre Gurin, Solaris Biotechnology Srl., PBS Biotech, Inc., ZETA GmbH, Applikon Biotechnology BV, Meissner Filtration Products, Inc., and Shanghai Bailun Biotechnology Co. Ltd.
Key Topics Covered
Executive Summary
1 Product Definition
2 Scope of the Work
2.1 Overview: Report Scope
2.2 Segmentation of the Global Next-Generation Biomanufacturing Market
2.3 Assumptions and Limitations
2.4 Key Questions Answered in the Report
2.5 Base Year and Forecast Period
3 Research Methodology
3.1 Overview: Report Methodology
4 Global Next-Generation Biomanufacturing Market Overview
4.1 Ever-Evolving Healthcare Scenario
4.2 Biomanufacturing: An Introduction
4.3 Upstream and Downstream Processing
4.4 Biopharmaceutical Market Growth Boosting Demand for Biomanufacturing
4.5 Key Technology Trends
4.6 The Future of Biomanufacturing: Next-Generation Biomanufacturing
4.7 Global Next-Generation Biomanufacturing Market Size
4.8 Market Dynamics
4.8.1 Impact Analysis of Market Dynamics
4.9 Assumptions and Limitations
5 Industry Insights
5.1 Overview
5.2 Regulatory Scenario
5.3 Patent Landscape
6 Competitive Landscape
6.1 Overview
6.2 Key Developments and Strategies
6.2.1 Partnerships and Alliances
6.2.2 Business Expansions
6.2.3 New Offerings
6.2.4 M & A Activities
6.2.5 Others
6.3 Market Share Analysis
7 Global Next-Generation Biomanufacturing Market (by Workflow and Product)
7.1 Overview
7.2 Upstream Biomanufacturing
7.2.1 Continuous Upstream Biomanufacturing Products
7.2.1.1 Bioreactors/Fermenters
7.2.1.2 Bags and Containers
7.2.1.3 Cell Culture Products
7.2.1.4 Filtration Systems
7.2.1.5 Mixing Systems
7.2.1.6 Sterilizers
7.2.1.7 Biosafety Cabinets
7.2.1.8 Incubators
7.2.1.9 Other Instruments and Accessories
7.2.2 Single-Use Upstream Biomanufacturing Products
7.2.2.1 Single-Use Bioreactors/Fermenters
7.2.2.2 Single-Use Bags and Containers
7.2.2.3 Single-Use Tubing and Connectors
7.2.2.4 Single-Use Mixing Systems
7.2.2.5 Single-Use Sensors and Probes
7.3 Downstream Processing
7.3.1 Downstream Biomanufacturing Products
7.3.1.1 Chromatography Systems
7.3.1.2 Filtration Systems
7.3.1.3 Membrane Adsorbers
7.3.1.4 Instruments and Accessories
7.3.1.5 Single-Use Equipment and Accessories
8 Global Next-Generation Biomanufacturing Market (by Medical Application)
8.1 Overview
8.2 Monoclonal Antibodies
8.3 Vaccines
8.4 Recombinant Proteins
8.5 Hormones
8.6 Others
9 Global Next-Generation Biomanufacturing Market (by End User)
9.1 Overview
9.2 Biopharmaceutical Companies
9.3 CMOs/CDMOs
9.4 Research Institutions
10 Global Next-Generation Biomanufacturing Market (by Region)
10.1 Overview
10.2 North America
10.3 Europe
10.4 Asia-Pacific
10.5 Latin America
10.6 Middle East & Africa
11 Company Profiles
11.1 Overview
11.2 Applikon Biotechnology B.V.
Go here to see the original:
Global Next-Generation Biomanufacturing Markets, 2019-2029: Focus on Workflow, Product Type, Medical Applications, End-users, and Competitive...
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023
- Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver - March 21st, 2023
- SANA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - March 21st, 2023
- Where Does Revance Therapeutics Inc (RVNC) Stock Fall in the Biotechnology Field After It Is Lower By -2.17% This Week? - InvestorsObserver - March 5th, 2023
- Is TG Therapeutics Inc common stock (TGTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 5th, 2023
- Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver - March 5th, 2023
- Where Does Dyne Therapeutics Inc (DYN) Stock Fall in the Biotechnology Field After It Is Lower By -2.35% This Week? - InvestorsObserver - March 5th, 2023
- Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 17th, 2022